enGene Therapeutics, Inc. (ENGN)
2.41
+0.13
(+5.70%)
USD |
NASDAQ |
Nov 13, 16:00
2.33
-0.08
(-3.32%)
After-Hours: 19:59
enGene Therapeutics Debt to Equity Ratio : 0.1445 for July 31, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| July 31, 2026 | 0.1445 |
| April 30, 2026 | 0.1307 |
| January 31, 2026 | 0.1189 |
| October 31, 2025 | 0.1896 |
| July 31, 2025 | 0.1564 |
| April 30, 2025 | 0.1116 |
| January 31, 2025 | 0.1006 |
| October 31, 2024 | 0.0918 |
| July 31, 2024 | 0.1079 |
| April 30, 2024 | 0.1016 |
| January 31, 2024 | 0.3931 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.0338 |
| July 31, 2023 | 0.00 |
| June 30, 2023 | 0.0198 |
| March 31, 2023 | 0.0035 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Aurinia Pharmaceuticals, Inc. | 0.0892 |
| Medicus Pharma Ltd. | -2.003 |
| Xenon Pharmaceuticals, Inc. | 0.0052 |
| Psyence Biomedical Ltd. | -- |
| Agenus, Inc. | -2.633 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 288.32M |
| Total Liabilities (Quarterly) | 58.03M |
| Shareholders Equity (Quarterly) | 230.29M |
| Current Ratio | 10.21 |
| Net Debt Paydown Yield | -1.32% |